NEW MOLECULAR ENTITY APPROVAL TIMES DOWN SLIGHTLY IN FIRST HALF OF 1995
Executive Summary
New molecular entities are being approved by FDA slightly faster in 1995 than last year, although the 11 NMEs approved to date do not exceed the number cleared by the agency in the first eight months of 1994. FDA will need at least as many approvals in the last four months of the year to meet the 22 NMEs approved last year.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth